MedTrace Logo

Pre-therapeutic Identification of Dihydropyrimidine Dehydrogenase Gene (DPD) Deficiency for Predicting Toxicity to Fluoropyrimidines

NCT01547923 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1142

Last updated 2020-03-25

No results posted yet for this study

Summary

The aim of this study is to demonstrate the medical and financial benefit of pre-therapeutic screening of DPD deficiency for predicting toxicity to fluoropyrimidines.

Conditions

Interventions

GENETIC

Blood sample for phenotypic and pharmacogenetic analysis.

Prior to treatment by 5-FU, a DPD deficiency is identified thanks to just one blood sample (lithium heparinate).

GENETIC

Blood sample for phenotypic and pharmacogenetic analysis.

Blood sample (lithium heparinate) will be taken prior to treatment but not analysed.

Sponsors & Collaborators

  • Institut Cancerologie de l'Ouest

    lead OTHER

Principal Investigators

  • Olivier Capitain, MD, PhD · Institut Cancerologie de l'Ouest

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-16
Primary Completion
2013-03-31
Completion
2013-03-04

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01547923 on ClinicalTrials.gov